These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 25992224)

  • 1. Modulation of insulin-like growth factor-1 receptor and its signaling network for the treatment of cancer: current status and future perspectives.
    Jin M; Buck E; Mulvihill MJ
    Oncol Rev; 2013 Apr; 7(1):e3. PubMed ID: 25992224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer.
    Singh P; Alex JM; Bast F
    Med Oncol; 2014 Jan; 31(1):805. PubMed ID: 24338270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin-like growth factor signaling as a therapeutic target in pancreatic cancer.
    Rieder S; Michalski CW; Friess H; Kleeff J
    Anticancer Agents Med Chem; 2011 Jun; 11(5):427-33. PubMed ID: 21492074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy.
    van der Veeken J; Oliveira S; Schiffelers RM; Storm G; van Bergen En Henegouwen PM; Roovers RC
    Curr Cancer Drug Targets; 2009 Sep; 9(6):748-60. PubMed ID: 19754359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin-like growth factor 1 receptor mediated tyrosine 845 phosphorylation of epidermal growth factor receptor in the presence of monoclonal antibody cetuximab.
    Iyer G; Price J; Bourgeois S; Armstrong E; Huang S; Harari PM
    BMC Cancer; 2016 Oct; 16(1):773. PubMed ID: 27716204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
    Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
    Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the insulin-like growth factor receptor pathway in lung cancer: problems and pitfalls.
    Fidler MJ; Shersher DD; Borgia JA; Bonomi P
    Ther Adv Med Oncol; 2012 Mar; 4(2):51-60. PubMed ID: 22423264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the insulin-like growth factor-1 receptor in human cancer.
    Arcaro A
    Front Pharmacol; 2013; 4():30. PubMed ID: 23525758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IGF-1R peptide vaccines/mimics inhibit the growth of BxPC3 and JIMT-1 cancer cells and exhibit synergistic antitumor effects with HER-1 and HER-2 peptides.
    Foy KC; Miller MJ; Overholser J; Donnelly SM; Nahta R; Kaumaya PT
    Oncoimmunology; 2014 Nov; 3(11):e956005. PubMed ID: 25941587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in targeting insulin-like growth factor signaling pathway in cancer treatment.
    You L; Liu C; Tang H; Liao Y; Fu S
    Curr Pharm Des; 2014; 20(17):2899-911. PubMed ID: 23944362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatocyte growth factor-induced mesenchymal-epithelial transition factor activation leads to insulin-like growth factor 1 receptor inhibitor unresponsiveness in gastric cancer cells.
    Liu R; Tang W; Han X; Geng R; Wang C; Zhang Z
    Oncol Lett; 2018 Nov; 16(5):5983-5991. PubMed ID: 30333869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside.
    Olmos D; Tan DS; Jones RL; Judson IR
    Cancer J; 2010; 16(3):183-94. PubMed ID: 20526094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IGF-1R as an anti-cancer target--trials and tribulations.
    Chen HX; Sharon E
    Chin J Cancer; 2013 May; 32(5):242-52. PubMed ID: 23601239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IGF system targeted therapy: Therapeutic opportunities for ovarian cancer.
    Liefers-Visser JAL; Meijering RAM; Reyners AKL; van der Zee AGJ; de Jong S
    Cancer Treat Rev; 2017 Nov; 60():90-99. PubMed ID: 28934637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advancements in small molecule inhibitors of insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase as anticancer agents.
    Negi A; Ramarao P; Kumar R
    Mini Rev Med Chem; 2013 Apr; 13(5):653-81. PubMed ID: 23373648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual targeting of the insulin-like growth factor and collateral pathways in cancer: combating drug resistance.
    Ludwig JA; Lamhamedi-Cherradi SE; Lee HY; Naing A; Benjamin R
    Cancers (Basel); 2011 Jul; 3(3):3029-54. PubMed ID: 24212944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling.
    Mitsiades CS; Mitsiades N
    Expert Rev Anticancer Ther; 2005 Jun; 5(3):487-99. PubMed ID: 16001956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer.
    Buck E; Gokhale PC; Koujak S; Brown E; Eyzaguirre A; Tao N; Rosenfeld-Franklin M; Lerner L; Chiu MI; Wild R; Epstein D; Pachter JA; Miglarese MR
    Mol Cancer Ther; 2010 Oct; 9(10):2652-64. PubMed ID: 20924128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of insulin-like growth factor receptor: end of a targeted therapy?
    Pillai RN; Ramalingam SS
    Transl Lung Cancer Res; 2013 Feb; 2(1):14-22. PubMed ID: 25806201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors in cancer therapy: advances and perspectives.
    Xue M; Cao X; Zhong Y; Kuang D; Liu X; Zhao Z; Li H
    Curr Pharm Des; 2012; 18(20):2901-13. PubMed ID: 22571659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.